

# AndzonBio2

## neuroinflammation

### **AndzonBio2 Strengthens Scientific and Strategic Capabilities with New Advisory Board and Leadership Appointment**

Paris, February 3, 2026.

AndzonBio2, a biotechnology company focused on developing innovative therapeutic programs in neuroinflammation, today announced the formation of its Scientific Advisory Board (SAB), comprised of leading experts in neuroscience, neurodegeneration, drug discovery, and translational development. The company also announced the appointment of Mounia Azzi, PhD, as Chief Business Officer, responsible for business development, strategic partnerships, and corporate initiatives.

The SAB will provide strategic guidance on the scientific and clinical development of AndzonBio2's programs and is chaired by Professor Michael Heneka, MD/PhD, Director of the Luxembourg Center for Systems Biomedicine and internationally recognized leader in neuroinflammation and neurodegenerative disease research.

He is joined by:

- Carol Routledge, PhD, former Alzheimer's Research UK, SV Health Investors, GSK
- Robert Hodgson, PhD, former Takeda, Merck, Charles River
- Prof. Isabelle Le Ber, MD/PhD, Paris Brain Institute
- Marion Wittmann, PhD, former Merck, Praxis, Biogen
- Jonathan Savidge, PhD, former Syndesi Therapeutics, Evotec, Proximagen
- Declan Jones, PhD, former GSK, Ferring, Johnson & Johnson

"Neuroinflammation is increasingly recognized as a key driver of neurodegenerative and neuropsychiatric diseases yet remains insufficiently addressed by current therapeutic approaches. AndzonBio2 is advancing innovative mechanisms that target upstream biology with real translational potential. I look forward to supporting the team as they progress these programs toward the clinic," said Michael Heneka, Chair of the SAB.

The Company also announced that Mounia Azzi, PhD, has joined AndzonBio2 as Chief Business Officer (part-time), bringing over 20 years of experience across biotech company creation, venture investment and strategic partnerships in the life sciences sector.

"We are delighted to welcome Mounia to the leadership team and to launch our SAB with such an exceptional group of advisors," said Loic Lhuillier, Chief Executive Officer of AndzonBio2. "Their

combined expertise in CNS drug development, translational neuroscience, and biotech innovation will be instrumental as we advance our programs and build strategic partnerships.”

AndzonBio2 is developing a portfolio of neuroinflammation-focused programs that leverage emerging mechanistic insights to address neurological disorders with high unmet medical need. The company operates through a collaborative, capital-efficient model with plans to pursue strategic partnerships to accelerate therapeutic development.

- 30 -

### **About AndzonBio2**

AndzonBio2 is a neuroscience company with a creative model structured to efficiently turn breakthrough science into therapeutic solutions that target the underpinning causes of neurological disease. The company has a strategic focus on neuroinflammation which is increasingly recognized as critically involved in multiple brain disorders. The company searches, evaluates and integrates the most promising European projects to build and advance a leading portfolio of balanced risk/reward assets in neurology.

### **For more information, please contact:**

Loic Lhuillier, PhD  
Chief Executive Officer and Co-Founder  
loic@andzonbio2.com